These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25445638)

  • 21. Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival.
    Alousi A; Wang T; Hemmer MT; Spellman SR; Arora M; Couriel DR; Pidala J; Anderlini P; Boyiadzis M; Bredeson CN; Cahn JY; Cairo MS; Gadalla SM; Hashmi SK; Gale RP; Kanda J; Kamble RT; Kharfan-Dabaja MA; Litzow MR; Ringden O; Saad AA; Schultz KR; Verdonck LF; Waller EK; Yared JA; Holtan SG; Weisdorf DJ
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):270-278. PubMed ID: 30292009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
    Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
    Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myelogenous leukemia: a study from the center for international blood and marrow transplantation research.
    Foran JM; Pavletic SZ; Logan BR; Agovi-Johnson MA; Pérez WS; Bolwell BJ; Bornhäuser M; Bredeson CN; Cairo MS; Camitta BM; Copelan EA; Dehn J; Gale RP; George B; Gupta V; Hale GA; Lazarus HM; Litzow MR; Maharaj D; Marks DI; Martino R; Maziarz RT; Rowe JM; Rowlings PA; Savani BN; Savoie ML; Szer J; Waller EK; Wiernik PH; Weisdorf DJ
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1102-8. PubMed ID: 23632091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient.
    Maury S; Balère-Appert ML; Chir Z; Boiron JM; Galambrun C; Yakouben K; Bordigoni P; Marie-Cardine A; Milpied N; Kanold J; Maillard N; Socié G;
    Haematologica; 2007 May; 92(5):589-96. PubMed ID: 17488681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia.
    Lorentino F; Labopin M; Ciceri F; Vago L; Fleischhauer K; Afanasyev B; Kröger N; Cornelissen JJ; Lovira M; Meijer E; Vitek A; Elmaagacli A; Blaise D; Ruggeri A; Chabannon C; Nagler A; Mohty M;
    Leukemia; 2021 Feb; 35(2):585-594. PubMed ID: 32409688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparable outcome after single-antigen-mismatched versus matched unrelated donor haematopoietic cell transplantation.
    Rockstroh A; Al-Ali HK; Lange T; Pönisch W; Krahl R; Cross M; Behre G; Niederwieser D; Pfrepper C
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2193-203. PubMed ID: 26129640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies.
    Sakellari I; Batsis I; Bousiou Z; Mallouri D; Constantinou V; Gavriilaki E; Smias C; Yannaki E; Kaloyannidis P; Papaioannou G; Stavroyianni N; Syrigou A; Sotiropoulos D; Fylaktou A; Tsompanakou A; Saloum R; Anagnostopoulos A
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):658-666. PubMed ID: 28716402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy.
    Nakaya A; Mori T; Tanaka M; Tomita N; Nakaseko C; Yano S; Fujisawa S; Sakamaki H; Aotsuka N; Yokota A; Kanda Y; Sakura T; Nanya Y; Saitoh T; Kanamori H; Takahashi S; Okamoto S
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1553-9. PubMed ID: 25034961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Experts' considerations on HLA-haploidentical stem cell transplantation.
    Patriarca F; Luznik L; Medeot M; Zecca M; Bacigalupo A; Di Bartolomeo P; Arcese W; Corradini P; Ciceri F; Vago L; Kanakry CG; Fleischhauer K; Martelli MF; Bosi A; Rambaldi A; Cesaro S; Russo D; Fanin R
    Eur J Haematol; 2014 Sep; 93(3):187-97. PubMed ID: 24660868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults.
    Peterlin P; Delaunay J; Guillaume T; Gastinne T; Mahé B; Dubruille V; Blin N; Le Bourgeois A; Brissot E; Lodé L; Le Gouill S; Moreau P; Mohty M; Chevallier P
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):180-4. PubMed ID: 25175796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts.
    Drobyski WR; Klein J; Flomenberg N; Pietryga D; Vesole DH; Margolis DA; Keever-Taylor CA
    Blood; 2002 Feb; 99(3):806-14. PubMed ID: 11806980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current Use and Trends in Hematopoietic Cell Transplantation in the United States.
    D'Souza A; Lee S; Zhu X; Pasquini M
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1417-1421. PubMed ID: 28606646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
    Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes.
    Duncan CN; Majhail NS; Brazauskas R; Wang Z; Cahn JY; Frangoul HA; Hayashi RJ; Hsu JW; Kamble RT; Kasow KA; Khera N; Lazarus HM; Loren AW; Marks DI; Maziarz RT; Mehta P; Myers KC; Norkin M; Pidala JA; Porter DL; Reddy V; Saber W; Savani BN; Schouten HC; Steinberg A; Wall DA; Warwick AB; Wood WA; Yu LC; Jacobsohn DA; Sorror ML
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):151-8. PubMed ID: 25316109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in the clinical impact of high-risk human leukocyte antigen allele mismatch combinations on the outcome of unrelated bone marrow transplantation.
    Kanda Y; Kanda J; Atsuta Y; Fuji S; Maeda Y; Ichinohe T; Takanashi M; Ohashi K; Fukuda T; Miyamura K; Mori T; Sao H; Kobayashi N; Iwato K; Sawada A; Mori S;
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):526-35. PubMed ID: 24417871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated Donor Using Tacrolimus/Sirolimus-based GvHD Prophylaxis: Impact of HLA Mismatch.
    Al Malki MM; Gendzekhadze K; Yang D; Mokhtari S; Parker P; Karanes C; Palmer J; Snyder D; Forman SJ; Nademanee A; Nakamura R
    Transplantation; 2020 May; 104(5):1070-1080. PubMed ID: 31449184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with Hematologic Malignancies.
    Bohannon L; Tang H; Page K; Ren Y; Jung SH; Artica A; Britt A; Islam P; Siamakpour-Reihani S; Giri V; Lew M; Kelly M; Choi T; Gasparetto C; Long G; Lopez R; Rizzieri D; Sarantopoulos S; Chao N; Horwitz M; Sung A
    Transplant Cell Ther; 2021 Aug; 27(8):669.e1-669.e8. PubMed ID: 33991725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy.
    Kollman C; Spellman SR; Zhang MJ; Hassebroek A; Anasetti C; Antin JH; Champlin RE; Confer DL; DiPersio JF; Fernandez-Viña M; Hartzman RJ; Horowitz MM; Hurley CK; Karanes C; Maiers M; Mueller CR; Perales MA; Setterholm M; Woolfrey AE; Yu N; Eapen M
    Blood; 2016 Jan; 127(2):260-7. PubMed ID: 26527675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamical System Modeling of Immune Reconstitution after Allogeneic Stem Cell Transplantation Identifies Patients at Risk for Adverse Outcomes.
    Toor AA; Sabo RT; Roberts CH; Moore BL; Salman SR; Scalora AF; Aziz MT; Shubar Ali AS; Hall CE; Meier J; Thorn RM; Wang E; Song S; Miller K; Rizzo K; Clark WB; McCarty JM; Chung HM; Manjili MH; Neale MC
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1237-45. PubMed ID: 25849208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.